Review



interferon λ  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    R&D Systems interferon λ
    Interferon λ, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 29 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/interferon λ/product/R&D Systems
    Average 93 stars, based on 29 article reviews
    interferon λ - by Bioz Stars, 2026-05
    93/100 stars

    Images



    Similar Products

    92
    Sino Biological recombinant mouse il 28b interferon lambda 3 sinobiological
    Recombinant Mouse Il 28b Interferon Lambda 3 Sinobiological, supplied by Sino Biological, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant mouse il 28b interferon lambda 3 sinobiological/product/Sino Biological
    Average 92 stars, based on 1 article reviews
    recombinant mouse il 28b interferon lambda 3 sinobiological - by Bioz Stars, 2026-05
    92/100 stars
      Buy from Supplier

    90
    Bristol Myers pegylated interferon lambda-1
    Pegylated Interferon Lambda 1, supplied by Bristol Myers, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pegylated interferon lambda-1/product/Bristol Myers
    Average 90 stars, based on 1 article reviews
    pegylated interferon lambda-1 - by Bioz Stars, 2026-05
    90/100 stars
      Buy from Supplier

    93
    R&D Systems interferon λ
    Interferon λ, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/interferon λ/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    interferon λ - by Bioz Stars, 2026-05
    93/100 stars
      Buy from Supplier

    90
    PBL Assay anti-human interferon lambda receptor 1 neutralizing antibody
    Anti Human Interferon Lambda Receptor 1 Neutralizing Antibody, supplied by PBL Assay, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti-human interferon lambda receptor 1 neutralizing antibody/product/PBL Assay
    Average 90 stars, based on 1 article reviews
    anti-human interferon lambda receptor 1 neutralizing antibody - by Bioz Stars, 2026-05
    90/100 stars
      Buy from Supplier

    93
    Kingfisher Biotech type iii interferon lambda 3 ifnl3
    Kinetics of virus replication following IBV challenge and addition of PEGylated IFN. PEGylated IFNA added at 8 h (IFNA-8), 24 h (IFNA-24), or 48 h (IFNA-48) post B/Phuket/3073/2013 challenge and compared to Mock treated group. PEGylated <t>IFNL3</t> added at 8 h (IFNL-8), 24 h (IFNL-24) or 48 h (IFNL-48) post challenge. NW titers determined on D1, D3, D5, and D7 post challenge (bar color indicating time of NW collection) and tested for virus Log FFU/mL by FFA. Significance between groups tested by 2-way ANOVA. Significant differences between IFNA-8 and IFNA-24 ( p = 0.0470) and IFNA-8 to IFNA-48 ( p = 0.0154) as well as IFNA-48 to IFNL-48 ( p = 0.0130). No significant differences noted between any groups with IFN added at 24 h and no significance compared to Mock-treated group.
    Type Iii Interferon Lambda 3 Ifnl3, supplied by Kingfisher Biotech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/type iii interferon lambda 3 ifnl3/product/Kingfisher Biotech
    Average 93 stars, based on 1 article reviews
    type iii interferon lambda 3 ifnl3 - by Bioz Stars, 2026-05
    93/100 stars
      Buy from Supplier

    90
    Federation of European Neuroscience Societies interferon-lambda
    Kinetics of virus replication following IBV challenge and addition of PEGylated IFN. PEGylated IFNA added at 8 h (IFNA-8), 24 h (IFNA-24), or 48 h (IFNA-48) post B/Phuket/3073/2013 challenge and compared to Mock treated group. PEGylated <t>IFNL3</t> added at 8 h (IFNL-8), 24 h (IFNL-24) or 48 h (IFNL-48) post challenge. NW titers determined on D1, D3, D5, and D7 post challenge (bar color indicating time of NW collection) and tested for virus Log FFU/mL by FFA. Significance between groups tested by 2-way ANOVA. Significant differences between IFNA-8 and IFNA-24 ( p = 0.0470) and IFNA-8 to IFNA-48 ( p = 0.0154) as well as IFNA-48 to IFNL-48 ( p = 0.0130). No significant differences noted between any groups with IFN added at 24 h and no significance compared to Mock-treated group.
    Interferon Lambda, supplied by Federation of European Neuroscience Societies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/interferon-lambda/product/Federation of European Neuroscience Societies
    Average 90 stars, based on 1 article reviews
    interferon-lambda - by Bioz Stars, 2026-05
    90/100 stars
      Buy from Supplier

    90
    Eiger BioPharmaceuticals Inc pegylated interferon lambda
    Kinetics of virus replication following IBV challenge and addition of PEGylated IFN. PEGylated IFNA added at 8 h (IFNA-8), 24 h (IFNA-24), or 48 h (IFNA-48) post B/Phuket/3073/2013 challenge and compared to Mock treated group. PEGylated <t>IFNL3</t> added at 8 h (IFNL-8), 24 h (IFNL-24) or 48 h (IFNL-48) post challenge. NW titers determined on D1, D3, D5, and D7 post challenge (bar color indicating time of NW collection) and tested for virus Log FFU/mL by FFA. Significance between groups tested by 2-way ANOVA. Significant differences between IFNA-8 and IFNA-24 ( p = 0.0470) and IFNA-8 to IFNA-48 ( p = 0.0154) as well as IFNA-48 to IFNL-48 ( p = 0.0130). No significant differences noted between any groups with IFN added at 24 h and no significance compared to Mock-treated group.
    Pegylated Interferon Lambda, supplied by Eiger BioPharmaceuticals Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pegylated interferon lambda/product/Eiger BioPharmaceuticals Inc
    Average 90 stars, based on 1 article reviews
    pegylated interferon lambda - by Bioz Stars, 2026-05
    90/100 stars
      Buy from Supplier

    90
    ZymoGenetics inc “lambda” is an investigational type iii interferon therapeutic agent
    Kinetics of virus replication following IBV challenge and addition of PEGylated IFN. PEGylated IFNA added at 8 h (IFNA-8), 24 h (IFNA-24), or 48 h (IFNA-48) post B/Phuket/3073/2013 challenge and compared to Mock treated group. PEGylated <t>IFNL3</t> added at 8 h (IFNL-8), 24 h (IFNL-24) or 48 h (IFNL-48) post challenge. NW titers determined on D1, D3, D5, and D7 post challenge (bar color indicating time of NW collection) and tested for virus Log FFU/mL by FFA. Significance between groups tested by 2-way ANOVA. Significant differences between IFNA-8 and IFNA-24 ( p = 0.0470) and IFNA-8 to IFNA-48 ( p = 0.0154) as well as IFNA-48 to IFNL-48 ( p = 0.0130). No significant differences noted between any groups with IFN added at 24 h and no significance compared to Mock-treated group.
    “Lambda” Is An Investigational Type Iii Interferon Therapeutic Agent, supplied by ZymoGenetics inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/“lambda” is an investigational type iii interferon therapeutic agent/product/ZymoGenetics inc
    Average 90 stars, based on 1 article reviews
    “lambda” is an investigational type iii interferon therapeutic agent - by Bioz Stars, 2026-05
    90/100 stars
      Buy from Supplier

    92
    R&D Systems human interferon λ1
    Analysis of <t>interferon</t> (‐response) genes upon coronavirus infection and effects of <t>IFN‐λ1</t> supplementation on viral load. (a) Volcano plots depicting shared gene expression profiles of bronchial epithelial cell cultures infected with SARS‐CoV, SARS‐CoV‐2 or MERS‐CoV for (a) 24, (b) 48 hpi or (c) 72 hpi in comparison to HCoV‐229E and HCoV‐OC43; n = 4. Red dots indicate significantly upregulated genes, and blue dots indicate significantly downregulated genes. (d) Heatmap of the overlap of significantly changed genes during 24, 48 and 72 hpi infection with SARS‐CoV‐2, SARS‐CoV, MERS‐CoV or HCoV‐229E or HCoV‐OC43 and mock as uninfected control. (e) Gene set variation analysis (GSVA) was performed on interferon response genes after 24, 48 and 72 hpi ( n = 4) in highly pathogenic (orange) and low pathogenic (blue) coronavirus‐infected cultures. As HCoV‐OC43 infection was conducted at 33°C, SARS‐CoV‐2 infection at 33°C was included as control (pink). (f) IFN‐λ1 and (g) IFN‐α1 gene expression after 24, 48 and 72 hpi ( n = 4) in highly pathogenic (orange) and low pathogenic (blue) coronavirus‐infected cultures. The error bar indicates the standard deviation. Significant differences in increased gene expression over time of infection ( P < 0.05) are shown by the * symbol. Two‐way ANOVA followed by an unprotected Fisher's least significance difference test was conducted to test for significance. (h) ALI‐PBEC cultures were pretreated with 5 ng mL −1 interferon lambda (IFN‐λ1) for 60 min and subsequently infected with SARS‐CoV‐2 for 3 days with IFN‐λ1 present in the basal medium. Extracellular viral RNA copies are depicted in log scale. Data in h were analysed with a paired t ‐test and are depicted as mean ± SEM. n = 4 independent donors.
    Human Interferon λ1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human interferon λ1/product/R&D Systems
    Average 92 stars, based on 1 article reviews
    human interferon λ1 - by Bioz Stars, 2026-05
    92/100 stars
      Buy from Supplier

    90
    Biotechnology Information sequence information of human interferon λ
    Analysis of <t>interferon</t> (‐response) genes upon coronavirus infection and effects of <t>IFN‐λ1</t> supplementation on viral load. (a) Volcano plots depicting shared gene expression profiles of bronchial epithelial cell cultures infected with SARS‐CoV, SARS‐CoV‐2 or MERS‐CoV for (a) 24, (b) 48 hpi or (c) 72 hpi in comparison to HCoV‐229E and HCoV‐OC43; n = 4. Red dots indicate significantly upregulated genes, and blue dots indicate significantly downregulated genes. (d) Heatmap of the overlap of significantly changed genes during 24, 48 and 72 hpi infection with SARS‐CoV‐2, SARS‐CoV, MERS‐CoV or HCoV‐229E or HCoV‐OC43 and mock as uninfected control. (e) Gene set variation analysis (GSVA) was performed on interferon response genes after 24, 48 and 72 hpi ( n = 4) in highly pathogenic (orange) and low pathogenic (blue) coronavirus‐infected cultures. As HCoV‐OC43 infection was conducted at 33°C, SARS‐CoV‐2 infection at 33°C was included as control (pink). (f) IFN‐λ1 and (g) IFN‐α1 gene expression after 24, 48 and 72 hpi ( n = 4) in highly pathogenic (orange) and low pathogenic (blue) coronavirus‐infected cultures. The error bar indicates the standard deviation. Significant differences in increased gene expression over time of infection ( P < 0.05) are shown by the * symbol. Two‐way ANOVA followed by an unprotected Fisher's least significance difference test was conducted to test for significance. (h) ALI‐PBEC cultures were pretreated with 5 ng mL −1 interferon lambda (IFN‐λ1) for 60 min and subsequently infected with SARS‐CoV‐2 for 3 days with IFN‐λ1 present in the basal medium. Extracellular viral RNA copies are depicted in log scale. Data in h were analysed with a paired t ‐test and are depicted as mean ± SEM. n = 4 independent donors.
    Sequence Information Of Human Interferon λ, supplied by Biotechnology Information, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sequence information of human interferon λ/product/Biotechnology Information
    Average 90 stars, based on 1 article reviews
    sequence information of human interferon λ - by Bioz Stars, 2026-05
    90/100 stars
      Buy from Supplier

    Image Search Results


    Kinetics of virus replication following IBV challenge and addition of PEGylated IFN. PEGylated IFNA added at 8 h (IFNA-8), 24 h (IFNA-24), or 48 h (IFNA-48) post B/Phuket/3073/2013 challenge and compared to Mock treated group. PEGylated IFNL3 added at 8 h (IFNL-8), 24 h (IFNL-24) or 48 h (IFNL-48) post challenge. NW titers determined on D1, D3, D5, and D7 post challenge (bar color indicating time of NW collection) and tested for virus Log FFU/mL by FFA. Significance between groups tested by 2-way ANOVA. Significant differences between IFNA-8 and IFNA-24 ( p = 0.0470) and IFNA-8 to IFNA-48 ( p = 0.0154) as well as IFNA-48 to IFNL-48 ( p = 0.0130). No significant differences noted between any groups with IFN added at 24 h and no significance compared to Mock-treated group.

    Journal: NPJ Vaccines

    Article Title: Interferon as an immunoadjuvant to enhance antibodies following influenza B infection and vaccination in ferrets

    doi: 10.1038/s41541-024-00973-2

    Figure Lengend Snippet: Kinetics of virus replication following IBV challenge and addition of PEGylated IFN. PEGylated IFNA added at 8 h (IFNA-8), 24 h (IFNA-24), or 48 h (IFNA-48) post B/Phuket/3073/2013 challenge and compared to Mock treated group. PEGylated IFNL3 added at 8 h (IFNL-8), 24 h (IFNL-24) or 48 h (IFNL-48) post challenge. NW titers determined on D1, D3, D5, and D7 post challenge (bar color indicating time of NW collection) and tested for virus Log FFU/mL by FFA. Significance between groups tested by 2-way ANOVA. Significant differences between IFNA-8 and IFNA-24 ( p = 0.0470) and IFNA-8 to IFNA-48 ( p = 0.0154) as well as IFNA-48 to IFNL-48 ( p = 0.0130). No significant differences noted between any groups with IFN added at 24 h and no significance compared to Mock-treated group.

    Article Snippet: Recombinant ferret type-I interferon alpha (IFNA) and type-III interferon lambda 3 (IFNL3) were purchased from Kingfisher Biotech, Inc. (Saint Paul, MN, USA).

    Techniques: Virus

    Analysis of interferon (‐response) genes upon coronavirus infection and effects of IFN‐λ1 supplementation on viral load. (a) Volcano plots depicting shared gene expression profiles of bronchial epithelial cell cultures infected with SARS‐CoV, SARS‐CoV‐2 or MERS‐CoV for (a) 24, (b) 48 hpi or (c) 72 hpi in comparison to HCoV‐229E and HCoV‐OC43; n = 4. Red dots indicate significantly upregulated genes, and blue dots indicate significantly downregulated genes. (d) Heatmap of the overlap of significantly changed genes during 24, 48 and 72 hpi infection with SARS‐CoV‐2, SARS‐CoV, MERS‐CoV or HCoV‐229E or HCoV‐OC43 and mock as uninfected control. (e) Gene set variation analysis (GSVA) was performed on interferon response genes after 24, 48 and 72 hpi ( n = 4) in highly pathogenic (orange) and low pathogenic (blue) coronavirus‐infected cultures. As HCoV‐OC43 infection was conducted at 33°C, SARS‐CoV‐2 infection at 33°C was included as control (pink). (f) IFN‐λ1 and (g) IFN‐α1 gene expression after 24, 48 and 72 hpi ( n = 4) in highly pathogenic (orange) and low pathogenic (blue) coronavirus‐infected cultures. The error bar indicates the standard deviation. Significant differences in increased gene expression over time of infection ( P < 0.05) are shown by the * symbol. Two‐way ANOVA followed by an unprotected Fisher's least significance difference test was conducted to test for significance. (h) ALI‐PBEC cultures were pretreated with 5 ng mL −1 interferon lambda (IFN‐λ1) for 60 min and subsequently infected with SARS‐CoV‐2 for 3 days with IFN‐λ1 present in the basal medium. Extracellular viral RNA copies are depicted in log scale. Data in h were analysed with a paired t ‐test and are depicted as mean ± SEM. n = 4 independent donors.

    Journal: Clinical & Translational Immunology

    Article Title: SARS ‐ C o V ‐2‐infected human airway epithelial cell cultures uniquely lack interferon and immediate early gene responses caused by other coronaviruses

    doi: 10.1002/cti2.1503

    Figure Lengend Snippet: Analysis of interferon (‐response) genes upon coronavirus infection and effects of IFN‐λ1 supplementation on viral load. (a) Volcano plots depicting shared gene expression profiles of bronchial epithelial cell cultures infected with SARS‐CoV, SARS‐CoV‐2 or MERS‐CoV for (a) 24, (b) 48 hpi or (c) 72 hpi in comparison to HCoV‐229E and HCoV‐OC43; n = 4. Red dots indicate significantly upregulated genes, and blue dots indicate significantly downregulated genes. (d) Heatmap of the overlap of significantly changed genes during 24, 48 and 72 hpi infection with SARS‐CoV‐2, SARS‐CoV, MERS‐CoV or HCoV‐229E or HCoV‐OC43 and mock as uninfected control. (e) Gene set variation analysis (GSVA) was performed on interferon response genes after 24, 48 and 72 hpi ( n = 4) in highly pathogenic (orange) and low pathogenic (blue) coronavirus‐infected cultures. As HCoV‐OC43 infection was conducted at 33°C, SARS‐CoV‐2 infection at 33°C was included as control (pink). (f) IFN‐λ1 and (g) IFN‐α1 gene expression after 24, 48 and 72 hpi ( n = 4) in highly pathogenic (orange) and low pathogenic (blue) coronavirus‐infected cultures. The error bar indicates the standard deviation. Significant differences in increased gene expression over time of infection ( P < 0.05) are shown by the * symbol. Two‐way ANOVA followed by an unprotected Fisher's least significance difference test was conducted to test for significance. (h) ALI‐PBEC cultures were pretreated with 5 ng mL −1 interferon lambda (IFN‐λ1) for 60 min and subsequently infected with SARS‐CoV‐2 for 3 days with IFN‐λ1 present in the basal medium. Extracellular viral RNA copies are depicted in log scale. Data in h were analysed with a paired t ‐test and are depicted as mean ± SEM. n = 4 independent donors.

    Article Snippet: ALI‐PBEC were pretreated with 5 ng mL −1 recombinant human interferon λ1 (IFN‐λ1; R&D Systems, Minneapolis, USA) for 60 min, and further infected with SARS‐CoV‐2 (estimated MOI of 1) with the presence of IFN‐λ1 in the basal medium.

    Techniques: Infection, Gene Expression, Comparison, Control, Standard Deviation